IDH1 and acute myeloid leukemia: In 2018, the IDH1 inhibitor ivosidenib was approved by the FDA for the treatment of patients with r/r IDH1-mutated AML [7] followed by approval by the FDA for patients with newly diagnosed IDH1-mutated AML not eligible for IC [56] in 2019.